Dublin, Oct. 04, 2024 (GLOBE NEWSWIRE) -- The Global Human Microbiome Market Forecast to 2030 report has been added to ResearchAndMarkets.com's offering.
The Human Microbiome market is expected to reach USD 4.2 billion in 2030 from USD 814.6 million in 2024, at a CAGR of 31.5% during the forecast period.
Factors such as the collaborative efforts between the microbiome industry and academia for microbiome research and the growing demand for personalized medicine are driving the growth of the Human Microbiome market. However, complex regulatory policies adversely impact the commercialization of microbiomes, restraining market growth.
Research Coverage
This research report categorizes the Human Microbiome market by Product (Drugs, Probiotics, Prebiotics, and others), Disease (Infectious disease, Gastrointestinal Disease, Endocrine, and metabolic disorders, Cancer, and Other Diseases), Type (Bacterial Consortia Transplantation (BCT)/Fecal Microbiota Transplantation (FMT), Peptides, Live Biotherapeutic Products, and Others) and by Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, challenges, opportunities, and restraints influencing the growth of the Human Microbiome market.
The probiotics segment accounted for the largest share by product segment in the human microbiome market in 2023
The market is analyzed across four key products: drugs, probiotics, prebiotics, and synbiotics. The segment with the biggest share in the Human Microbiome market in 2023 is Probiotics, Driven by increasing consumer awareness about the benefits of probiotics for gut health, immunity, and overall wellness. Still, the Prebiotics segment held the second-largest market share. Additionally, widespread consumer demand and acceptance as health supplements along with active research supporting health claims on probiotics supports the segment growth. The market is also propelled by the growing popularity of functional foods and beverages containing probiotics.
Asia Pacific is growing at the highest CAGR in the human microbiome market from 2024 to 2030
The Asia Pacific is estimated to be the fastest-growing segment of the market primarily due to the increasing awareness of microbiome health, emerging healthcare and biotechnology industries, government support, and funding potential for personalized medicine. The development of high - throughout sequencing technologies has made it possible to sequence the entire mircrobiome in a single sample, enabling researchers to more accurately and comprehensively characterize the microbial communities that are present in samples. Challenges in terms of data protection and privacy, as well as high cost of human mircrobiomes, are expected to restrain the growth of the Asia- pacific market. In addition, there may be cultural and linguistic barriers to adoption in certain region, as well as concerns about the accuracy and clinical utility of microbiome sequencing data.
Competitive Landscape
A detailed analysis of the key industry players has been done to provide insights into their business overview, service portfolio, key strategies such as collaborations, partnerships, expansions, agreements, and acquisitions, and recent developments associated with the Human Microbiome market. Competitive analysis of top players and upcoming startups in the Human Microbiome market ecosystem is covered in this report.
Major Companies Profiled in the Report
- Nestle SA (Switzerland)
- Ferring Pharmaceuticals (Switzerland)
- BiomeBank (Australia)
- Seed Health, Inc. (US)
- International Flavors & Fragrances Inc. (US)
- Pendulum (US)
- BioHM Health Inc. (US)
- Actial Farmaceutica SRL (Italy)
- Optibiotix Health plc (UK)
- Resbiotic (US)
- Infinant Health Inc (US)
- Biogaia AB (Sweden)
- Exegi Pharma LLC (US)
Key Attributes
| Report Attribute | Details |
| No. of Pages | 291 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value (USD) in 2024 | $814.6 Million |
| Forecasted Market Value (USD) by 2030 | $4206 Million |
| Compound Annual Growth Rate | 31.5% |
| Regions Covered | Global |
Market Dynamics
- Drivers
- Collaborative Initiatives Between Organizations and Academia in Microbiome Industry
- Increasing Number of Start-Ups/SMEs Exploring Microbiome Niche
- Advancements in Microbiome Sequencing
- Restraints
- Adverse Impact of Complex Regulatory Policies on Commercialization of Microbiomes
- High Investments in Commercialization of Microbiome Drugs
- Opportunities
- Increasing Demand for Personalized Medicine
- Emergence of Postbiotics
- Challenges
- Slow Patient Adoption of Microbiome-based Therapies
- Complexities Involved in Development of Microbiome Therapies
Pricing Analysis
- Average Selling Price of Human Microbiome Drugs, by Key Player
- Average Cost Range of Human Microbiome Products, 2021-2023
- Average Selling Price Analysis, by Region
Industry Assessment
- Pipeline Analysis
- Patent Analysis
- Ecosystem Analysis
- Supply Chain Analysis
- Value Chain Analysis
- Investment & Funding Scenario
- Regulatory Analysis
Technology Analysis
- Key Technologies
- Whole-Genome Sequencing
- 16S RNA Sequencing Method
- Nanopore Sequencing
- Complementary Technologies
- Metatranscriptomics
- Metagenomics
- Metabolomics
- Adjacent Technologies
- Sample Preparation
- Data Analysis
- Library Synthesis
Case Study Analysis
- Effect of Rebyota on Quality of Life in Patients with Recurrent Clostridioides Difficile Infection
- Ecospor IV Study of Vowst for Clostridioides Difficile Infection
- Delong#3 Study for Quality of Life Improvement by Vsl#3 Probiotic in Post-COVID-19 Patients
List of Companies Featured in the Report
- International Flavors & Fragrances, Inc.
- Seed Health, Inc.
- Pendulum
- Seres Therapeutics
- Ferring Pharmaceuticals
- BiomeBank
- BioHM Health Inc.
- Actial Farmaceutica Srl
- Optibiotix Health PLC
- Resbiotic
- Infinant Health Inc.
- Biogaia AB
- Exegi Pharma, LLC
- Aobiome
- Guangzhou Zhiyi Biotechnology Co. Ltd.
- Nubiyota
- Oxthera AB
- Nexbiome
- Vedanta Biosciences, Inc.
- Enterome
- Apsen Farmaceutica SA
- Metagen Therapeutics, Inc.
- Snipr Biome
- Maat Pharma SA
- Mikrobiomik
For more information about this report visit https://www.researchandmarkets.com/r/z780si
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
